General Clinical Chemistry Analyzers and Accessories
Abcam MM-102 (HMTase Inhibitor I x ), 5MG
MW 669.8 Da, Purity >=98%. MM-102 (HMTase Inhibitor IX) is a potent WDR5/MLL interaction inhibitor (IC50 = 2.4 nM). It has been shown to block MLL1 methyltransferase activity, reducing the expression of HoxA9 and Meis-1 genes, which are both critical MLL1 target genes in MLL1 fusion protein-mediated leukemogenesis. WD-repeat protein 5 (WDR5) is a scaffold protein commonly involved in the formation of nucleosome-modifying protein complexes with histones.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sunitinib, Free base, 100MG
MW 398.5 Da, Purity >=99%. Sunitinib is a free base form of Sunitinib malate. A CSF-1 receptor kinase inhibitor .
The product is subject to the following: Abcam Restricted Use Statement
Abcam WH-4-023, 25MG
MW 568.7 Da, Purity >98%. Potent and selective inihbitor of the tyrosine kinases Lck and Src with IC₅₀ values of 2 nM for Lck and 6 nM for Src.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sulforhodamine 101 cadaverine trifluoroacetic salt, 5MG
MW 1381.8 Da, Purity >90%. Stable, bright red fluorescent label for proteins. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 5MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 100MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 10MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DREADD Agonist 21, DREADD agonist, 1MG
MW 278.35 Da, Purity >98%. Potent, selective muscarinic hM3Dq DREADD (Designer Receptors Exclusively Activated by Designer Drugs) agonist (EC₅₀ = 1.7 nM). Highly selective for hM₃Dq over endogenous hM₃ receptors.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 50MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 50MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dabrafenib, mutant B-Raf V600E inhibitor, 25MG
MW 519.6 Da, Purity >98%. Potent, ATP-competitive mutant B-Raf V600E inhibitor (IC50 = 0.7 nM), with selectivity versus wild-type B-Raf (IC50 = 5.2 nM) and c-RAf (IC50 = 6.3 nM) in cell-free assays. Antitumor activity *in vivo* in mouse models of B-Raf V600E melanoma.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dovitinib, class III-V receptor tyrosine kinase inhibitor, 5MG
MW 392.4 Da, Purity >99%. Potent, selective inhibitor of class III-V receptor tyrosine kinases (RTKs). Inhibits FLT3 (IC₅₀ = 1 nM), c-KIT (IC₅₀ = 2 nM), FGFR (IC₅₀ = 8 nM), VEGFR1/2/3 (IC₅₀ values are 10 nM, 13 nM and 8 nM respectively), PDGFRβ (IC₅₀ = 27 nM), and CSF-1R (IC₅₀ = 36 nM). Selectively blocks growth of B9 cells transformed by wild type, or activated mutant FGFR3. Induces apoptosis, or sensitizes cells to induction of apoptosis by other means in a variety of cancer cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Kifunensine, class I alpha-mannosidase inhibitor, 1MG
MW 232.19 Da. Cell-permeable, potent, selective inhibitor of class I α-mannosidases. (IC₅₀ = 20-50 nM for mung bean α-1,2-mannosidase I). Alkaloid originally isolated from the actinomycete Kitasatosporia kifunense. Used to suppress Endoplasmic Reticulum-Associated Degradation (ERAD) via the inhibition of endoplasmic reticulum-associated mannosidase activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Kifunensine, class I alpha-mannosidase inhibitor, 5MG
MW 232.19 Da. Cell-permeable, potent, selective inhibitor of class I α-mannosidases. (IC₅₀ = 20-50 nM for mung bean α-1,2-mannosidase I). Alkaloid originally isolated from the actinomycete Kitasatosporia kifunense. Used to suppress Endoplasmic Reticulum-Associated Degradation (ERAD) via the inhibition of endoplasmic reticulum-associated mannosidase activity.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen Flibanserin
Chemical. CAS 167933-07-5. Formula C20H21F3N4O. MW 390.4. Synthetic. Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A Ki=1nm and 49nM, respectively. It also binds to dopamine D4 receptors with Ki values ranging from 4-24nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder HSDD. Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinson‘s Disease.